Introduction
Seropositive rheumatoid arthritis (RA) in adult and juvenile patients is associated with the serologic marker HLA-DR4. This association is incomplete; about one-third of the patients lack the disease-associated HLA-DR4 haplotype. The main biological function of class II molecules is to restrict the recognition of antigen by T lymphocytes. We therefore tested the hypothesis that patients with seropositive RA share T cell recognition sites for an unknown antigen and that such T cell "epitopes" are not identified by conventional serologic typing. We generated alloreactive human T cell clones by stimulating peripheral blood lymphocytes of normal donors against a lymphoblastoid cell line from a juvenile patient with seropositive RA. A panel of clones that recognized only HLA-Dw14 cells on a panel of homozygous typing cells was used to analyze class II molecules of adult patients with seropositive RA. By inhibition studies using monoclonal antibodies, the epitopes recognized by the different clones could be further characterized and assigned either to DR-or to DQ-encoded cell surface products. By using four different clones, it was possible to identify Dwl4-associated T cell epitopes on all seropositive rheumatoid patients tested who typed HLA-DR4-positive and also on all eight DR4-negative patients tested. Approximately one-half of nonrheumatoid DR4-positive donors carried one or more determinants recognized by these clones; the expression of these allodeterminants in DR4-negative nonrheumatoid patients was rare (<10%). Thus, alloreactive human T cell clones are powerful tools to define T cell recognition sites on class II molecules that are not identified by conventional typing. Using T cell clones with specificities for determinants expressed on Dw14 homozygous typing lines, we were able to demonstrate shared epitopes on cells of all patients tested with seropositive RA irrespective of their HLA-D or HLA-DR type. These data suggest that major histocompatibility complex class II antigens of RA patients might be much more homogeneous than demonstrated by the incomplete HLA-DR4 association.
Receivedfor publication 24 June 1985 and in revisedform 26 November 1985. The highly polymorphic cell surface glycoproteins encoded within the human major histocompatibility complex (MHC)' serve to restrict the recognition of antigen by T cells (1, 2) . Recognition of epitopes on nominal antigens, together with MHC determinants, is a necessary event for the activation of T lymphocytes. Several human diseases, most ofwhich are characterized by autoimmune phenomena, have been associated with HLA determinants, in particular with MHC class II (HLA-D) molecules (3) (4) (5) . These MHC class II molecules function as restriction elements for T helper cells (6) . T helper cells are responsible for the initiation of immune responses against most antigens. Thus, the ability of the immune system to recognize and eliminate antigens is determined in part by the structure and function of the MHC molecules. "Inappropriate recognition" of antigen in association with the T cell recognition sites on MHC class II molecules could cause "abnormal" immune responses and might be the explanation for the association of certain autoimmune diseases with particular MHC Class II molecules.
Human MHC class II molecules have been defined and characterized by conventional serologic techniques as HLA-DR specificities, and by mixed lymphocyte reactions as HLA-D specificities. By cellular typing, the serologically defined HLA-DR4 specificity has been divided into five subgroups: Dw4, DwlO, Dwl 3, Dw14, and Dwl 5 (7-9). 60-80% of patients with seropositive rheumatoid arthritis (RA) are HLA-DR4-positive (10) (11) (12) (13) . HLA-DR4 is the haplotype associated with the seropositive form of rheumatoid arthritis (RA) in many different ethnic groups (14) (15) (16) providing strong evidence that this haplotype may play a major role in susceptibility to the disease. An etiologic agent for RA has not been identified; thus the antigens that might be involved in triggering the disease are unknown. We hypothesized that the striking association of seropositive RA with HLA-DR4 is in part due to a specific polymorphism(s) within MHC class II molecules that can lead to an arthritogenic recognition of a yet unknown antigen by T lymphocytes. It has been shown that functionally relevant alterations of T cell re-striction elements are reflected by changes in T cell epitopes recognized as allodeterminants (17) . Because there is no identified disease-causing antigen for RA, we generated human alloreactive T cell clones which were then used to analyze class II molecules ofcells from patients with RA. We developed a panel of T cell clones that defined distinct HLA-DR4-related T cell epitopes on HLA-DR-and HLA-DQ-encoded molecules. On homozygous typing cells, a panel of these clones recognized determinants present only on Dwl4-positive cell lines. When these clones were tested on patients with seropositive RA, one or more of these Dwl4-related determinants could be identified on all patients tested (n = 23) irrespective of their HLA-D and HLA-DR type. These data suggest that patients with RA share T cell epitopes that are not recognized by conventional typing.
Methods
Preparation ofperipheral blood lymphocytes (PBL). Heparinized venous blood was diluted with an equal volume of RPMI 1640 medium and separated by density gradient centrifugation on Ficoll-Hypaque. Cells within the interface layer were washed three times and resuspended in RPMI 1640 supplemented with 10% fetal calf serum.
Generation of alloreactive T cell clones. Alloreactive T cell clones were isolated and maintained as described (18) . Briefly, 5 X 105/ml responder cells were stimulated by 5 X 105/ml irradiated (10,000 rads) lymphoblastoid cells from a DR4 homozygous Dw4/Dw14 heterozygous patient with juvenile seropositive RA in 20 ml of complete culture medium (RPMI 1640 supplemented with 10% fetal calf serum and 2 mM L-glutamine). PBL of five different healthy donors were used as responders: four of them shared one DR4 haplotype with the stimulator, the fifth typed DR2, negative. Every 2 wk, bulk cultures were restimulated with 5 X 105/ml irradiated Epstein-Barr virus (EBV) blasts and tested for antigen responsiveness to the primary stimulators in a proliferation assay at day 4. 6-8 wk after initiation of the bulk culture, T cells were cloned by the technique of limiting dilution. Viable T cells were plated (0.3 cell/well) in the presence of irradiated stimulators cells and 2 U/ well recombinant interleukin 2 (IL-2) (Cetus Corporation, Emeryville, CA) in 96-well flat-bottomed trays. Growing clones, observed microscopically, were transferred to 24-well Costar plates together with fresh antigen and IL-2-containing medium. Established T cell clones were maintained in IL-2-enriched complete medium and were restimulated with alloantigen at 2-wk intervals.
T cell proliferation assay. Proliferative responses of the alloreactive T cell clones were determined in a thymidine incorporation assay as described (18) . Briefly, rested T cells ( 0,000-20,000/well) were cocultured with irradiated EBV blasts (30,000/well) or irradiated PBL (100,000/ well) in triplicate cultures in 200 ,l of complete culture medium in 96-well round-bottomed trays (Linbro, Flow Laboratories, McLean, VA). Generally, the total culture time was 60 h, for the last 12 h, the cultures were pulsed with 1 MiCi [3H]thymidine/well. After harvesting the cultures on glass fiber filters, thymidine incorporation was measured by liquid scintillation spectroscopy. Results are expressed as the antigen-specific thymidine uptake (difference in counts per minute, Acpm), which was calculated by subtracting the mean counts per minute without responders from the mean counts per minute from responder-stimulator cocultures. Without added antigen, the cloned cells incorporated below 300 cpm; the counts per minute of stimulators alone were in the range of 500-1,500. Standard errors of the triplicate cultures were <20%. To allow comparison of the results obtained in different assays, Bin40, LS40, and autologous controls were included in all experiments and proliferative responses to the individual stimulators were expressed as a percent fraction of the maximum thymidine uptake induced by Bin40 (relative response). A relative response of <20% was defined as negative.
Target inhibition by monoclonal antibodies. Before the initiation of the culture, 3 X 10' irradiated stimulator cells were incubated with serial dilutions of monoclonal antibodies (5 Mg/well to 0.03 gg/well). The fol- RA and were chosen for the study. All of them had a disease duration of > 1 yr and were rheumatoid factor-positive. The control group consisted of randomly collected unrelated healthy donors, whose cells were HLA-DR typed. Additionally, 10 healthy individuals who were known to be DR4-positive were included in the controls. (Table I) . 65% of the patients typed DR4 (Table II) , which is in accord with the known HLA-DR4 association of seropositive RA (1 1), and is more than twice the frequency of DR4 in a normal population (22 (Table VA) and CB 1-15 (see Table VA and Fig. 2 ) and allowed thfe assignment of their T cell recognition sites (epitopes) to DR encoded molecules. The determinant seen by clone Cl-19 has been previously shown to be located on a DQ region product (18) . Monoclonal antibody blocking studies demonstrated that the T cell epitopes seen by clone C2-4 and clone 2-6 were also on DQ molecules (Table VA) . Thus, the alloreactive human T cell clones allowed the definition of four T cell recognition sites (epitopes) on DR molecules and three T cell epitopes on DQ molecules. The determinants defined by the seven clones described here were arbitrarily named as follows: DR-T 1, DR-T2, DR-T3, and DR-T4 for the T cell epitopes encoded by the DRregion and DQ-TI, DQ-T2, and DQ-T3 for the T cell target structures expressed by DQ molecules (Table VB) . Distribution ofTcell recognition sites on MHC class II molecules ofpatients with seropositive RA. Proliferative responses of these seven alloreactive T cell clones were tested on the 23 patients described in Table I . The patients' cells were typed for the HLA-D specificity Dw14 using PLT reagents. Of the 23 RA patients, only 2 ofthe 15 DR4-positive patients and none ofthe 8 DR4-negative patients induced a positive typing response for HLA-Dw14. Thus, the frequency ofHLA-Dwl4 defined by PLT was not increased in patients with seropositive RA. Although we would have predicted that only the two Dwl4-positive patients' cells would stimulate this panel of T cell clones, this was not the case. All cells tested from seropositive RA patients were seen by at least one of four of these clones. The T cell epitopes defined by the panel ofT cell clones were expressed on different subpopulations of the patients. Although the specificities seen by the different clones were associated with HLA-DwI4 on the homozygous typing cell lines, the Dw14 associated T cell epitopes were present on cells from RA patients who were Dw 14-negative and DR4-negative.
The determinants in DR-T2 and DR-T3 were found on only one patient (data not shown). In contrast, the T cell epitopes DR-TI and DR-T4 were seen frequently within the patients' group. The proliferative responses of clone T4-3 1 (recognizing DR-T1) and clone CB1-15 (recognizing DR-T4) on the panel of 23 RA patients are shown in Fig. 1 A. The determinant DR-Ti was identified in the majority of the DR4-positive patients, and, in addition, was expressed by two DR4-negative patients who shared the HLA-DRI haplotype. A similar phenomenon was observed for the determinant DR-T4. This epitope was expressed by most ofthe DR4-positive RA patients, but additionally by two DR4-negative RA patients both of whom typed Dw8. The DQ-encoded epitopes DQ-T1, DQ-T2, and DQ-T3 were less frequent among the patients. DQ-T2 was found on a subset of DQ-T1 positive patients (data not presented). Proliferation of clone C2-1 and clone C2-6 in response to the 23 RA patients is shown in Fig. 1 B. The DQencoded determinants do not cluster with DR-Ti and DR-T4 epitopes, despite the fact that all of these determinants are concurrently expressed on the DwI4-positive homozygous typing lines (Table III) . Patients who did not carry the HLA-DR4 DQw3 haplotype induced proliferation of the two DQ-specific T cell clones C2-1 and C2-6, indicating that conventional serologic techniques do not identify T cell recognition sites. Thus, T cell epitopes, the combination ofwhich defines the HLA-D specificity , are very frequent but independently distributed in patients with seropositive RA. Each patient of the group of 23 RA patients tested expressed at least one of the following four allodeterminants: DR-Tl, DR-T4, DQ-T1, and DQ-T3 ( Fig.  1 A and B) .
Differential blocking patterns of clone CB1-15 in DR4 and non-DR4 haplotypes. CB1-15 proliferated in response to two RA patients sharing the Dw8 haplotype. CB 1-15 could be blocked by monoclonal antibodies specific for DR-encoded molecules on both DR4 and Dw8 haplotypes indicating that the epitope DR-T4 is located on a DR a-f3 dimer (Fig. 2) . Clone C2-1 and clone C2-6 are specific for DQ products (B). Proliferative response was ob-DR2, negative individual. 18 DR4-positive normal (nonrheumatoid) donors were tested for the presence ofthe determinants defined by the panel ofalloreactive T cell clones described above. As shown in Table VI , two clearly distinct groups could be differentiated: half of the individuals were negative for the four T cell epitopes DR-Tl, DR-T4, DQ-T1, and DQ-T3. The other 50% of the healthy donors expressed one or more of the T cell epitopes seen by the clones. Although determinants DR-T2 and DR-T3 were present on only one patient with seropositive RA, they had a similar frequency to DR-T1 and DR-T4 within the normal population (4 out of 18) and were coexpressed on targets positive for DR-TI or DR-T4 (data not presented). 
Discussion
The association of seropositive RA with HLA-DR4 is well established (10) (11) (12) (13) . This association has been interpreted as demonstration of a susceptibility factor which might be inherited within or in strong linkage to the HLA-D region. Genes within the HLA-D region encode cell surface molecules which are used by T cells as restricting elements for the recognition of foreign antigens (1 1, 12) . We addressed the question ofwhether patients with seropositive RA share MHC class II-encoded T cell restriction elements which might initiate a "pathogenic" immune response leading to a disease process manifested by a variety of Alloantigen-induced proliferation was measured as described in Table  III (17) . Thus, alloreactive T lymphocytes should be appropriate reagents to analyze the immunologically relevant fine specificities of HLA-D molecules for HLA and disease associations. Interestingly, previous attempts to strengthen the HLA-DR4 association with RA by conventional cellular typing techniques have failed (23, 24) . Although Dw4 was the predominant HLA-D specificity associated with RA, the association was less than the HLA-DR4 relationship. We have recently developed alloreactive human T cell clones to dissect HLA-D specificities. Using such clones, we were able to show that a positive typing response in mixed lymphocyte reactions giving rise to HLA-D assignment is elicited by the recognition of a combination of different T cell epitopes (18 The T cell clones used in this study were established by stimulation ofPBL against a B lymphoblastoid cell line from a patient with seropositive juvenile rheumatoid arthritis (JRA). This disease is similar to the adult form of seropositive RA. Class II molecules on the cells from the JRA patient had been previously characterized by detailed cellular typing and biochemical analysis (25) . A panel of seven different T cell clones was developed. Based on differences in target inhibition studies with monoclonal antibodies and distinct recognition patterns on a panel of stimulator cells, these clones defined different T cell recognition sites related to HLA-DwI4 (Table VB) . In a group of adult RA patients, the individual T cell epitopes were very frequent; however, the concurrent expression of multiple determinants, equivalent to the cellular type HLA DwI4, was a rare event. Surprisingly, T cell epitopes DR-T1, DR-T4, DQ-TI, DQ-T2, and DQ-T3 were found on cells of patients that did not type HLA-DR4. About one-third of the patients were HLA-DR4-negative, but all of them were identified by at least one of four of the T cell clones. The presence of an allodeterminant defined by the panel of clones used in this study in nonrheumatoid HLA-DR4-negative donors was rare (2 of 23).
The analysis of cells from a group of nonrheumatoid DR4-positive individuals allowed their classification into two subgroups. Half of the donors did not express any of the determinants seen by this panel of clones, whereas the second half was characterized by a random distribution of the epitopes recognized by these clones. Thus, with regard to the presence of the described class II that genetic markers which are present in patients with RA must also be present in DR4-positive nonrheumatoid individuals substantiating the idea that rheumatoid arthritis is a multicausal disease including genetic and environmental factors (29) . For certain non-Caucasian ethnic groups, HLA-DRl has been described as a genetic marker associated with seropositive RA (30, 31) . Evidence that the phenotypes HLA-DRl and HLA-DR4 share determinants has been provided by the use of alloantiserum Te23 and different monoclonal antibodies (32, 33) . Recently, a new MHC class II specificity, MCI, expressed on most DRl and DR4 haplotypes has been reported to be associated with adult rheumatoid arthritis (34) . The T cell recognition site DR-Tl was present in two non-DR4-positive patients sharing the HLA-DRl haplotype. It is possible that shared T cell epitopes between DRl and DR4 explain increased frequencies of DRl in RA. The determinant DR-T4 was present in two patients who typed HLA-DRw8. No association between seropositive RA and HLA-DRw8 has yet been described.
In speculating about mechanisms that might give rise to T 
